With the Medical & Science division as a Business Line, we have a specific focus on these industries. 

Based in Indianapolis, Indiana, U.S.A., Eli Lilly and Company is among the top 10 global pharmaceutical companies. Since it was founded 135 years ago, Lilly has always been committed to discovering, developing and marketing innovative drugs worldwide, and the number of molecules in the last phase of development currently in the pipeline is the highest since its foundation.  
Lilly is among the 5 world leaders in several treatment areas that are crucial for public health, including diabetes, oncology, neurosciences and veterinary pharmaceuticals, and each one has one of the strongest pipelines of molecules under development. Elanco (Lilly’s veterinary division) is among the company with the fastest growth rate in its sector, with sales doubling over the past five years and expected to double again over the next five year period.  
Throughout its history, Lilly has made possible some of the most significant discoveries of modern medicine: from the introduction in the 20s of the first insulin available on the market worldwide, to the first vaccines against typhoid fever and poliomyelities, from the development of a method for the industrial production of penicillin to the introduction of a wide range of antibiotics and early anticancer drugs. In the 80s, Lilly launched the first drug in the world based on recombinant DNA technology: an insulin identical to that produced by the human body. In those same years the company also introduced fluoxetine, the first product of a new class of drugs for the treatment of depression. The 1990s saw the development of other innovative molecules like gemcitabine for the treatment of pancreatic, lung, bladder and breast cancer, and olanzapine, the most used antipsychotic in the world for the treatment of schizophrenia and bipolar disorder. More recently, Lilly has introduced products like pemetrexed, the first treatment for pleural mesotelioma; teriparatide for the treatment of osteoporosis; tadalafil that is the first treatment for erectile dysfunction and urinary symptoms problems; duloxetine for the treatment of major depression, and prasugrel for patients with acute coronary syndrome treated with angioplasty. 

Lilly constantly invests in human resources, offering competitive salaries, training and development, health and wellness to its employees worldwide; and has ranked for many years as one of the best employers to work for.
Research & Development 
Lilly is a leader in scientific research and development of new drugs through growing investment in biotechnologies, personalized treatments and advanced analytics. In the last few years the company has established partnerships and alliances to expand its ability to search for and access ideas, talents and new molecules under development.  In 2012, investments in Research and Development amounted to over $ 5 billion, or 20% of the company’s financial resources. The new drugs being researched concern therapeutic areas where pressing global demand has not yet received adequate response, including: neurosciences, diabetes and obesity, oncology, self-immune diseases.
Lilly and social responsibility
The company has created a global partnership to fight chronic diseases and has been promoted since years a partnership against multiresistant tuberculosis donating millions of dollars to fund re-search for the discovery of a new cure for tuberculosis.
Lilly worldwide  
Lilly total revenue 2013: $ 23,113 billion +2% (2013 vs 2012) 
Net income 2013: $ 4,684 billion $ +15% (2013 vs. 2012)
Total no. of employees: 38,000, 7,800 in R&D
Research and Development sites in 8 countries 
13 production sites
Products marketed in 125 countries
Lilly Italia
Lilly’s Italian subsidiary was started approximately 50 years ago with headquarters in Sesto Fiorentino, Florence. 
Today, Lilly Italia covers a surface of 43,000 square meters, employs over 1,000 people, and has constantly improved its scientific, production and financial results, with revenues of 770 million in 2013 with more than 15 million invested in R&D. In the Sesto Fiorentino area the company has built Italy’s largest plant for the production of biotechnology drugs, and particularly of recombinant DNA insulin for EU and non EU countries. In 2013, for the second year, Lilly Italia was awarded a prestigious recognition by the “Great Place To Work” Institute as best Italian pharmaceutical company to work for.